CompuMed Seeks Patent Protection for Use of OsteoGram(R) on Digital Mammography Equipment New Capability to be Debuted at RSNA LOS ANGELES, Nov. 23 /PRNewswire-FirstCall/ -- CompuMed, Inc. (OTC:CMPD) (BULLETIN BOARD: CMPD) -- a developer of Computer Aided Diagnostic (CAD) solutions for the healthcare industry -- today announced that it has filed a provisional U.S. patent application for the integration and use of its OsteoGram osteoporosis screening/diagnostic software system on digital mammography equipment. This latest application of the OsteoGram will use images taken by digital mammography equipment to perform osteoporosis testing at the same time women undergo routine mammograms. Mammography equipment is used to screen millions of women worldwide for breast cancer, and digital mammography platforms are a high growth segment of the breast cancer screening field. "Integrating the OsteoGram with digital mammography equipment will help solve the myriad of public health problems caused by inadequate testing and diagnosis of osteoporosis in its early stages," said Jerry McLaughlin, CompuMed's CEO. "We are making it possible for women to have their bone density tested at the same time they have their routine mammograms." The OsteoGram is a medical image processing system that enables healthcare providers to screen, diagnose and monitor osteoporosis using digital images from filmless x-ray equipment, or conventional, film-based hand x-rays. The software-based imaging system is far less costly and cumbersome than conventional bone mineral density (BMD) testing systems, which require dedicated and expensive equipment, computers, office space and staff. Osteoporosis is a silent disease that affects more than 44 million Americans and costs the nation's health care system in excess of $17 billion annually. About half of all women over the age of 50 will experience a bone fracture due to osteoporosis. Hip fractures are by far the most devastating, accounting for 300,000 hospitalizations each year in the U.S. alone, and resulting in more deaths than breast cancer. The new OsteoGram capability will be introduced at the 90th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago (November 29-December 3). The OsteoGram system will be on display with Fujifilm Medical's (Div. Fuji Photo ADR; NASDAQ: FUJIY) ClearView-CSm* CR digital mammography image reader at the Fuji exhibit (McCormick Place North Building, booth # 7332). "Combining low cost osteoporosis screening with digital mammography is a concept whose time has come," added McLaughlin. About RSNA: The Radiological Society of North America (RSNA) is an association of more than 33,000 radiologists, radiation oncologists and related scientists committed to promoting excellence in patient care. Its Scientific Assembly and Annual Meeting in Chicago (November 28-December 3) comprise the world's largest medical imaging exhibition, featuring more than 600 leading manufacturers, suppliers and developers of radiology products and services. Visit RSNA at http://www.rsna.org/. About CompuMed: Founded in 1973, CompuMed, Inc. (OTC:CMPD) (BULLETIN BOARD: CMPD) is a leading provider of computer-aided telemedicine and diagnostics technology. The company's core products are the OsteoGram and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The CardioGram has the additional capability to automatically provide an over-read (i.e., follow- up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at http://www.compumed.net/. This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. *The ClearView -CSm requires FDA approval and is not commercially available in the U.S. DATASOURCE: CompuMed, Inc. CONTACT: Erik Deutsch of Tellem Worldwide, +1-310-479-6111, ext. 15, , for CompuMed, Inc. Web site: http://www.rsna.org/ Web site: http://www.compumed.net/

Copyright